Recently approved cholesterol medication not cost-effective; could substantially increase US health costs
Although the recently FDA approved cholesterol-lowering drugs, PCSK9 inhibitors, could substantially reduce heart attacks, strokes, and cardiovascular deaths, they would not be cost-effective for use in patients with heterozygous ...
Aug 16, 2016
0
1